CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7): sc-293188

CB2 Antibody (3C7) is a mouse monoclonal IgG1 kappa light chain antibody that detects CB2 of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-CB2 antibody (3C7) is available as the non-conjugated isotype antibody. CB2, a member of the cannabinoid receptor family, is primarily expressed in immune cells, distinguishing CB2 from CB1, which is predominantly found in the brain. This unique expression pattern suggests CB2 plays a significant role in modulating immune responses and inflammation, making CB2 a potential therapeutic target for various immune-related disorders. Activation of CB2 by cannabinoids can lead to anti-inflammatory effects, which are important in conditions such as arthritis and multiple sclerosis. Furthermore, interaction of CB2 with specific proteins, such as β-arrestins, can influence downstream signaling pathways, thereby affecting cellular responses to cannabinoids. Understanding these interactions and functional implications of CB2 activation is vital for developing targeted therapies that harness the therapeutic potential of cannabinoids while minimizing psychoactive effects.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7) References:

1. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.  |  Sugiura, T., et al. 2000. J Biol Chem. 275: 605-12. PMID: 10617657
2. The endogenous cannabinoid system and brain development.  |  Fernández-Ruiz, J., et al. 2000. Trends Neurosci. 23: 14-20. PMID: 10631784
3. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors.  |  Valverde, O., et al. 2000. Eur J Neurosci. 12: 533-9. PMID: 10712632
4. Molecular cloning of a human cannabinoid receptor which is also expressed in testis.  |  Gérard, CM., et al. 1991. Biochem J. 279 (Pt 1): 129-34. PMID: 1718258
5. Structure of a cannabinoid receptor and functional expression of the cloned cDNA.  |  Matsuda, LA., et al. 1990. Nature. 346: 561-4. PMID: 2165569
6. Endocannabinoid engagement of CB2 regulates RSV-induced immunity.  |  Kaplan, BLF. 2018. Virulence. 9: 494-495. PMID: 29338583
7. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.  |  Gado, F., et al. 2019. Future Med Chem. 11: 2019-2037. PMID: 31517528
8. Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation.  |  Stasiulewicz, A., et al. 2023. J Chem Inf Model. 63: 1012-1027. PMID: 36693026
9. Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.  |  Hosoki, H., et al. 2024. Life Sci. 355: 123002. PMID: 39173999
10. Molecular characterization of a peripheral receptor for cannabinoids.  |  Munro, S., et al. 1993. Nature. 365: 61-5. PMID: 7689702
11. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.  |  Shire, D., et al. 1996. Biochim Biophys Acta. 1307: 132-6. PMID: 8679694
12. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.  |  Ledent, C., et al. 1999. Science. 283: 401-4. PMID: 9888857

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7) has 26 citations in a variety of scientific publications.

Primary antibodies like Anti-CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7) Specifications

Alternate Product Name: Cannabinoid receptor 2

Product Clone Name: 3C7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 302-360

Epitope Target: CB2

Epitope Species: human

Product Reactivity/Detection: CB2

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 26 citations in various scientific publications

Available Conjugates/Forms for CB2/Cannabinoid Receptor 2/CNR2 Antibody (3C7): N/A